Karyopharm (KPTI) EVP executes automatic share sale for tax withholding

Rhea-AI Filing Summary

Karyopharm Therapeutics Inc. executive Reshma Rangwala, EVP & Chief Medical Officer, reported an open-market sale of 5,066 shares of common stock at an average price of $9.4095 per share. After this transaction, she held 56,739 shares directly.

According to the disclosure, the sale was executed under a pre-established durable automatic sale instruction plan adopted on April 4, 2022. The shares were sold by a broker to cover withholding tax obligations arising from the vesting of restricted stock units, and the filing states that the transaction did not represent a discretionary trade by the reporting person.

Insider Trade Summary

Net Seller: 5,066 shares ($47,669)

Net Sell 1 txn

Insider Rangwala Reshma

Role EVP & Chief Medical Officer

Sold 5,066 shs ($48K)

Type	Security	Shares	Price	Value
Sale	Common Stock	5,066	$9.4095	$48K

Holdings After Transaction: Common Stock — 56,739 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rangwala Reshma

(Last) (First) (Middle)

C/O KARYOPHARM THERAPEUTICS INC.

85 WELLS AVENUE

(Street)

NEWTON MA 02459

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Karyopharm Therapeutics Inc. [ KPTI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP & Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/02/2026		S(1)		5,066	D	$9.4095	56,739	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on April 4, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.

	/s/ Nancy Smith as Attorney-in-Fact for Reshma Rangwala	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Karyopharm Therapeutics (KPTI) report for Reshma Rangwala?

Karyopharm Therapeutics reported that EVP & Chief Medical Officer Reshma Rangwala sold 5,066 shares of common stock. The sale was executed at an average price of $9.4095 per share and was tied to tax withholding on vested restricted stock units.

Was the KPTI insider stock sale by Reshma Rangwala a discretionary trade?

No, the filing states the sale was not a discretionary trade. It was executed under a durable automatic sale instruction plan adopted on April 4, 2022, specifically to cover withholding tax liabilities from the vesting of restricted stock units.

How many KPTI shares does Reshma Rangwala hold after the reported transaction?

After the reported sale, Reshma Rangwala directly holds 56,739 shares of Karyopharm Therapeutics common stock. This figure reflects her remaining direct ownership following the 5,066-share broker-assisted sale to satisfy tax withholding obligations on vested restricted stock units.

What price did the KPTI insider sale by Reshma Rangwala achieve per share?

The reported insider sale by Reshma Rangwala was executed at an average price of $9.4095 per share. This price applies to the 5,066 shares sold in a broker-assisted transaction designed to cover tax withholding from restricted stock unit vesting.

Why did Karyopharm’s EVP & Chief Medical Officer sell KPTI shares?

The sale was made to satisfy withholding tax liabilities arising from the vesting of restricted stock units. The filing explains it was a broker-assisted, automatic sale under a durable instruction plan, rather than a discretionary decision to trade Karyopharm Therapeutics stock.

What plan governed the KPTI insider sale reported for Reshma Rangwala?

The transaction was carried out under a durable automatic sale instruction plan adopted by Reshma Rangwala on April 4, 2022. The plan authorized broker-assisted sales to cover tax withholding obligations when her restricted stock units vest.